Discovery of NR2B-selective antagonists via scaffold hopping and pharmacokinetic profile optimization
Authors:
- 1 May 2019
- journal article
- research article
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 29 (9) , 1143-1147
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Discovery of orally bioavailable cyclohexanol-based NR2B-selective NMDA receptor antagonists with analgesic activity utilizing a scaffold hopping approachBioorganic & Medicinal Chemistry Letters, 2017
- Allosteric modulators of NR2B‐containing NMDA receptors: molecular mechanisms and therapeutic potentialBritish Journal of Pharmacology, 2009
- Amide-containing NR2B/NMDA receptor antagonistsExpert Opinion on Therapeutic Patents, 2006
- Glutamate-based therapeutic approaches: NR2B receptor antagonistsCurrent Opinion in Pharmacology, 2006
- Cloning and expression of the human NMDA receptor subunit NR3B in the adult human hippocampusNeuroscience Letters, 2005
- Activation of NR1/NR2B NMDA receptorsNature Neuroscience, 2003
- Genetic enhancement of inflammatory pain by forebrain NR2B overexpressionNature Neuroscience, 2001
- A Practical Synthesis of 4-(Substituted-benzyl)piperidines and (±)-3-(Substituted-benzyl)pyrrolidines via a Wittig ReactionThe Journal of Organic Chemistry, 1999
- Glutamate in CNS disorders as a target for drug development: an updateDrug News & Perspectives, 1998
- N-methyl-D-aspartic acid receptor structure and functionPhysiological Reviews, 1994